LYDERM 0.05 %
FLUOCINONIDE : 0.05 % · DIN 02236996 · TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.
Health Canada status: MARKETED
What is LYDERM?
LYDERM 0.05 % contains FLUOCINONIDE : 0.05 %. It is listed in the Health Canada Drug Product Database under DIN 02236996, held by TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC., supplied as OINTMENT for TOPICAL administration. Health Canada currently lists it as marketed, status dated 07-Dec-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LYDERM used for?
LYDERM (fluocinonide) is indicated for topical therapy of corticosteroid responsive acute and chronic skin eruptions where an anti-inflammatory, anti-allergenic and anti-pruritic activity in the topical management is required.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is LYDERM called?
The same molecule, FLUOCINONIDE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| FLUSKIN | Latin | Morocco |
| TOPSYNE APG | Latin | Morocco |
| TOPSYNE GEL | Latin | Morocco |
| TOPSYNE GRAS | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02236996 |
|---|---|
| Brand name | LYDERM |
| Generic / active ingredient | FLUOCINONIDE : 0.05 % |
| Manufacturer | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. |
| Strength | 0.05 % |
| Dosage form | OINTMENT |
| Route of administration | TOPICAL |
| Schedule | Prescription |
| ATC code | D07AC08 FLUOCINONIDE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 07-Dec-2023 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02236996 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2236996 |
| Brand name | LYDERM |
| Active ingredient / INN | FLUOCINONIDE : 0.05 % |
| ATC code | D07AC08 |
| ATC anatomical main group | D — Dermatologicals |
| ATC therapeutic subgroup | D07 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. |
How is it stored and handled?
room temperature (15°C - 30°C)
How is it supplied?
15 g and 60 g collapsible tubes, 400 g plastic jars
Which pack is which?
| Strength on the label | 0.05 % |
|---|---|
| Dosage form | OINTMENT |
| Route | TOPICAL |
| Packaging as described in the monograph | 15 g and 60 g collapsible tubes, 400 g plastic jars |
| Storage | room temperature (15°C - 30°C) |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code D07AC08 FLUOCINONIDE. 4 of 18 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| LYDERM | 0.05 % | CREAM | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. | MARKETED | DIN 00716863 |
| LYDERM | 0.05 % | GEL | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. | MARKETED | DIN 02236997 |
| TIAMOL CREAM 0.05% | 0.05 % | CREAM | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. | MARKETED | DIN 00598933 |
| LIDEMOL | 0.05 % | CREAM | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 02163152 |
| LIDEMOL 0.05% | Strength | Cream , Emulsion | SYNTEX INC. 2455 Meadowpine Blvd. Mississauga Ontario Canada L5N 6L7 | CANCELLED POST MARKET | DIN 00424943 |
| LIDEX | 0.05 % | OINTMENT | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 02161966 |
| LIDEX | 0.05 % | CREAM | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 02161923 |
| LIDEX | 0.05 % | GEL | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 02161974 |
| LIDEX CREAM MILD 0.01% | 0.01 % | CREAM | MEDICIS CANADA LTD. | CANCELLED POST MARKET | DIN 00274453 |
| LIDEX OINTMENT MILD 0.01% | 0.01 % | OINTMENT | MEDICIS CANADA LTD. | CANCELLED POST MARKET | DIN 00274445 |
How much does FLUOCINONIDE cost around the world?
FLUOCINONIDE is listed on 3 national price registers Nexara tracks, across 56 pack listings published on 3 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 5 | 50 | 03 Sep 2026 |
| Morocco | PPV (public price) | 4 | 4 | 05 Sep 2026 |
| Greece | producer price (ex-factory) | 2 | 2 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.